Status: Not yet recruiting
Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.
Participants needed: 120
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Universität MünsterUpdated: Sep 29, 2025Locations: 1
Eligibility criteria
Subjects with histologically confirmed relapsed/refractory DLBCL based on pathol... [+26]
Any prior lymphoma-directed treatment, except for first-line anti-CD20-/anthracy... [+28]